The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone call and a commitment to reach patients with sickle cell disease wherever in the world they live.
“When Albert called me, the first thing he said was, ‘You guys have really been amazing in what you’ve done in such a short period of time,’” said Ted Love, Global Blood’s CEO, recalling for me his conversation with Pfizer CEO Albert Bourla.
Then came Bourla’s pitch. “He told me Pfizer was excited to deploy its resources and global footprint to address all the patients,” Love said.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.